Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Alessio Cortellini, Katia Cannita, Marcello Tiseo, Diego L. Cortinovis, Joachim G.J.V. Aerts, Cinzia Baldessari, Raffaele Giusti, Miriam G. Ferrara, Ettore D'Argento, Francesco Grossi, Annalisa Guida, Rossana Berardi, Alessandro Morabito, Carlo Genova, Lorenzo Antonuzzo, Francesca Mazzoni, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Giada TargatoFrancesca Rastelli, Rita Chiari, Danilo Rocco, Stefania Gori, Michele De Tursi, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Sergio Bracarda, Fabrizio Citarella, Russano Marco, Luca Cantini, Olga Nigro, Sebastiano Buti, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria R. Migliorino, Salvatore Natalizio, Carnio Simona, Marco De Filippis, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian P. Spinelli, Massimo Di Maio, Giuseppe L. Banna, Alex Friedlaender, Alfredo Addeo, David J. Pinato

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study'. Together they form a unique fingerprint.

Medicine & Life Sciences